Small-Scale Bioreactors Market to Hit US$7.71 Billion by 2033

The small-scale bioreactors market is projected to be valued US$ 7.71 billion by 2033. Over the course of the projected period, the market is anticipated to grow at a CAGR of 14.8%. The market is projected by FMI to be valued US$ 1.94 billion in 2023.

New therapies are expected to be increasingly developed in the coming years due to the increased likelihood demand for dedicated manufacturing processes. These processes can be successfully achieved by the use of small-scale bioreactors, consequently leading to their high demand.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16931

As the years go by, automation and control systems are constantly improving alongside. As a result, it is expected to become easier to optimize and regulate small-scale bioreactors, making them more cost-friendly and efficient.

Moreover, heightened adoption of ceaseless manufacturing processes has been witnessed. Thus, gaining popularity in the pharmaceutical industry is aptly suited for the use of small-scale bioreactors. The booming pharmaceutical industry is expected to be favorable for these bioreactors in the years to come.

Advances in gene and cell therapies and their consequent approval by relevant authorities are expected to enhance the market scope for small-scale bioreactors. This can be ascribed to the increasing demand for scalable and versatile manufacturing processes. Thus leading to successful recognition by the use of small-scale bioreactors.

Immunization campaigns throughout the world over are expected to enhance product sales in the stipulated time frame. Moreover, government bodies across the world are financially supporting biopharmaceutical research. For instance, in April 2020, the government of South Korea allocated US$ 250 million to introduce the Vaccine Innovative Technology Alliance (VITAL). This is expected to help with vaccine production, research, and use.

Going forward, the demand for personalized medicine is anticipated to grow. As a result, the demand for small-scale bioreactors to develop small batches of customized therapies is expected to bolster market growth. In addition to this, the market is also observing an upsurge in the trend of patient-centric healthcare.

Top Highlights from the FMI’s Analysis of the Small-scale Bioreactors Market:

The 1L–3L capacity segment led the market, by acquiring more than 31% of the total market revenue in 2022.
The reusable bioreactors segment held more than 80.05% in 2022 and is predicted to maintain its dominance in the years to come.
The single-use bioreactors segment is anticipated to expand at a robust pace over the forecast period.
The North America market is expected to lead the market over the stipulated time frame.
The Asia Pacific market is projected to expand at a robust pace in the assessment period.

Key Updates from the Small-scale Bioreactors Market Regarding its Competitive Side:

In December 2022, Inceptor Bio and Ori Biotech came together to support the nascent level process development. To upscale the growth of Inceptor’s distinct CAR-M, CAR-NK, and CAR-T programs. Inceptor Bio is a third partner to sign up for LightSpeed Early Access Program (LEAP) by Ori. The company can now deploy the fully automated CGT manufacturing platform and digital capabilities before its commercial availability.
In April 2022, Lonza and Luzhu Biotech entered a commercial and research license agreement. The agreement aims to utilize GS piggyBac transposon technology and Gene Expression System by Lonza.

Small-scale Bioreactors Market by Category

By Product, the Small-scale Bioreactors Industry is segmented as: